Cost-Effectiveness of Aspirin Use Among Persons With Newly Diagnosed Type 2 Diabetes
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All
i


Cost-Effectiveness of Aspirin Use Among Persons With Newly Diagnosed Type 2 Diabetes

Filetype[PDF-159.21 KB]



Details:

  • Alternative Title:
    Diabetes Care
  • Description:
    OBJECTIVE To assess the long-term cost-effectiveness of aspirin use among adults aged ≥40 years with newly diagnosed type 2 diabetes. RESEARCH DESIGN AND METHODS We used a validated cost-effectiveness model of type 2 diabetes to assess the lifetime health and cost consequences of use or nonuse of aspirin. The model simulates the progression of diabetes and accompanying complications for a cohort of subjects with type 2 diabetes. The model predicts the outcomes of type 2 diabetes along five disease paths (nephropathy, neuropathy, retinopathy, coronary heart disease, and stroke) from the time of diagnosis until age 94 years or until death. RESULTS Over a lifetime, aspirin users gained 0.31 life-years (LY) or 0.19 quality-adjusted LYs (QALYs) over nonaspirin users, at an incremental cost of $1,700; the incremental cost-effectiveness ratio (ICER) of aspirin use was $5,428 per LY gained or $8,801 per QALY gained. In probabilistic sensitivity analyses, the ICER was <$30,000 per QALY in all of 2,000 realizations in two scenarios. CONCLUSIONS Regular use of aspirin among people with newly diagnosed diabetes is cost-effective.
  • Source:
    Diabetes Care. 33(6):1193-1199.
  • Document Type:
  • Collection(s):
  • Main Document Checksum:
  • File Type:

You May Also Like

Checkout today's featured content at stacks.cdc.gov